(Q34586272)

3 August 2017

1 reference

title

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab (English)

1 reference

3 August 2017

Fernando Rivera

1

1 reference

3 August 2017

Ma Eugenia Vega-Villegas

series ordinal

2

1 reference

3 August 2017

Marta F Lopez-Brea

series ordinal

3

1 reference

3 August 2017

Raul Marquez

series ordinal

4

1 reference

3 August 2017

1 January 2008

1 reference

3 August 2017

1 reference

3 August 2017

47

1 reference

3 August 2017

9-19

1 reference

3 August 2017

1

1 reference

The protein tyrosine kinase family of the human genome

3 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Her signaling in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Cetuximab in the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Cetuximab in the treatment of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

The evolving role of cetuximab in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Current status of cetuximab for the treatment of patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Targeted therapy trials: approval strategies, target validation, or helping patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

FDA drug approval summary: panitumumab (Vectibix).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Panitumumab in colon cancer: a review and summary of ongoing trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Biology of interactions: antiepidermal growth factor receptor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860701704724

10.1080/02841860701704724

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference